Sudapharma Security Rating

Arovella Therapeutics (formerly known as SUDA Pharmaceuticals) is a pharmaceutical company focusing on the delivery of drugs across the oral mucosa using its proprietary OroMist technology. Its product pipeline includes ZolpiMist, a spray formulation of zolpidem tartrate for the short-term treatment of insomnia; ArTiMist, a sub-lingual spray for the treatment of p. falciparum severe pediatric malaria; and Midazolam, a flavored oral spray formulation for the treatment of epileptic seizures and pre-procedure anxiety in imaging and dental procedures. The company also develops oral spray formulations for the treatment of acute migraine, postoperative and chemotherapy-induced nausea and vomiting, as well as erectile dysfunction.